Back to Search
Start Over
Risk adapted post-transplant maintenance in multiple myeloma.
- Source :
-
Expert review of hematology [Expert Rev Hematol] 2019 Feb; Vol. 12 (2), pp. 107-118. - Publication Year :
- 2019
-
Abstract
- Introduction: The survival of multiple myeloma patients is increasing due to new medications, the widespread implementation of autologous stem cell transplantation and better supportive treatments. The controversy surrounding post-transplant treatment is debated due to a lack of large randomized trials comparing the different treatment modalities. The questions for each proposed treatment are whether it improves outcomes, has low cumulative toxicities and is easy to administer. Areas covered: In this review, we have summarized the current data on maintenance therapy in newly diagnosed MM patients undergoing ASCT, focusing on bortezomib, thalidomide and lenalidomide as well as newer agents Expert opinion: Maintenance treatment has been shown to deepen and prolong responses and increase PFS and OS. Lenalidomide is approved for maintenance and guidelines recommend its use post ASCT. Ixazomib has recently been reported to improve PFS.
- Subjects :
- Antineoplastic Combined Chemotherapy Protocols therapeutic use
Humans
Maintenance Chemotherapy methods
Transplantation, Autologous
Antineoplastic Agents therapeutic use
Bortezomib therapeutic use
Hematopoietic Stem Cell Transplantation methods
Lenalidomide therapeutic use
Multiple Myeloma therapy
Thalidomide therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1747-4094
- Volume :
- 12
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Expert review of hematology
- Publication Type :
- Academic Journal
- Accession number :
- 30696304
- Full Text :
- https://doi.org/10.1080/17474086.2019.1576521